$CLX

CLOROX CO /DE/

CIK:0000021076|SEC Filings

CONSOLIDATED STATEMENTS OF EARNINGS - USD ($) shares in Thousands, $ in Millions	12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Net sales	$ 6,720	$ 7,104	$ 7,093
Cost of products sold	3,876	3,891	4,045
Gross profit	2,844	3,213	3,048
Selling and administrative expenses	1,066	1,124	1,167
Advertising costs	749	770	832
Research and development costs	116	121	126
Loss on divestiture	0	118	240
Pension settlement charge	0	0	171
Interest expense	130	88	90
Other (income) expense, net	(8)	(86)	24
Earnings before income taxes	791	1,078	398
Income taxes	190	254	106
Net earnings	601	824	292
Less: Net earnings attributable to noncontrolling interests	14	14	12
Net earnings attributable to Clorox	$ 587	$ 810	$ 280
Net earnings per share attributable to Clorox
Basic net earnings per share (in dollars per share)	$ 4.82	$ 6.56	$ 2.26
Diluted net earnings per share (in dollars per share)	$ 4.81	$ 6.52	$ 2.25
Weighted average shares outstanding (in thousands)
Basic (in shares)	121,775	123,525	124,174
Diluted (in shares)	122,132	124,287	124,804

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2024
Operating activities:
Net earnings	$ 601	$ 824	$ 292
Adjustments to reconcile net earnings to net cash provided by operations:
Depreciation and amortization	247	219	235
Stock-based compensation	48	81	74
Deferred income taxes	81	(18)	(100)
Venture agreement payment	476	0	0
Loss on divestiture	0	112	238
Pension settlement charge	0	0	171
Other	(7)	(26)	26
Changes in:
Receivables, net	151	(145)	(34)
Inventories, net	(71)	63	55
Prepaid expenses and other current assets	2	(9)	25
Accounts payable and accrued liabilities	38	(124)	(140)
Operating lease right-of-use assets and liabilities, net	(4)	2	0
Income taxes payable/prepaid	2	2	(147)
Net cash provided by operations	612	981	695
Investing activities:
Capital expenditures	(207)	(220)	(212)
Business acquired, net of cash acquired	(2,104)	0	0
Proceeds from divestiture, net of cash divested	0	128	17
Other	10	(2)	20
Net cash used for investing activities	(2,301)	(94)	(175)
Financing activities:
Notes and loans payable, net	1,078	0	(45)
Debt borrowings, net of issuance costs paid	2,737	0	0
Debt repayments	(1,250)	0	0
Treasury stock purchased	(256)	(332)	0
Cash dividends paid to Clorox stockholders	(602)	(602)	(595)
Cash dividends paid to noncontrolling interests	(16)	(16)	(16)
Issuance of common stock for employee stock plans and other	(23)	26	1
Net cash provided by (used for) financing activities	1,668	(924)	(655)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2)	0	(26)
Net increase (decrease) in cash, cash equivalents and restricted cash	(23)	(37)	(161)
Cash, cash equivalents and restricted cash:
Beginning of year	170	207	368
End of year	147	170	207
Supplemental cash flow information:
Interest paid	122	97	102
Income taxes paid, net of refunds	104	264	347
Noncash financing activities:
Cash dividends declared and accrued, but not paid	$ 16	$ 16	$ 16

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2026	Jun. 30, 2025
Current assets
Cash and cash equivalents	$ 143	$ 167
Receivables, net	791	821
Inventories, net	777	523
Prepaid expenses and other current assets	113	97
Total current assets	1,824	1,608
Property, plant and equipment, net	1,512	1,267
Operating lease right-of-use assets	401	333
Goodwill	1,945	1,229
Trademarks, net	989	502
Other intangible assets, net	606	64
Other assets	517	558
Total assets	7,794	5,561
Current liabilities
Notes and loans payable	1,086	4
Current maturities of long-term debt	1	0
Current operating lease liabilities	86	87
Accounts payable and accrued liabilities	1,600	1,828
Total current liabilities	2,773	1,919
Long-term debt	3,981	2,484
Long-term operating lease liabilities	366	305
Other liabilities	405	351
Deferred income taxes	17	20
Total liabilities	7,542	5,079
Commitments and contingencies
Stockholders’ equity
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding	0	0
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of June 30, 2026 and 2025; and 120,926,454 and 122,694,263 shares outstanding as of June 30, 2026 and 2025, respectively	131	131
Additional paid-in capital	1,312	1,319
Retained earnings	386	432
Treasury stock, at cost: 9,815,007 and 8,047,198 shares as of June 30, 2026 and 2025, respectively	(1,582)	(1,404)
Accumulated other comprehensive net (loss) income	(157)	(157)
Total Clorox stockholders’ equity	90	321
Noncontrolling interests	162	161
Total stockholders’ equity	252	482
Total liabilities and stockholders’ equity	$ 7,794	$ 5,561